The AJMC® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.
April 24th 2024
Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
A Managed Care Focus on Assessing the Armamentarium for Multiple Sclerosis to Better Individualize Treatment
1.5 Credits / Neurology
View More
The Promising Role of Novel and Emerging Therapies for Amyotrophic Lateral Sclerosis: Clinical and Managed Care Insights
1.0 Credit / Neurology
View More
Strategies for the Management and Treatment of ALS: The Value of Early Diagnosis and Clinical Intervention
3.0 Credits / Neurology
View More
Leveraging Managed Care to Optimize Best Practices in the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
1.0 Credit / Neurology
View More
Improving Outcomes and Quality of Care in Spinal Muscular Atrophy: Updates in Treatment Advances
2.0 Credits / Neurology
View More
New and Emerging Treatment Strategies for Myasthenia Gravis: The Role of the Specialty Pharmacist
1.0 Credit / Neurology
View More
Improving Treatment Access for Spinal Muscular Atrophy: How Managed Care Strategies Can Ease Clinical and Caregiver Burden
1.5 Credits / Neurology
View More
Assessing the Treatment Landscape for Multiple Sclerosis to Better Individualize Care
1.5 Credits / Neurology
View More
Immune System Changes May Increase Efficacy of Treatment for Secondary Progressive MS
January 25th 2020Shifting towards an anti-inflammatory and suppressive homeostatic immune system may contribute to increased clinical efficacy of siponimod in patients with secondary progressive multiple sclerosis (SPMS), a recent study in JCI Insight reported.
Read More
MTX Treatment May Increase Risk of Developing Late Left Ventricular Dysfunction in Patients with MS
January 20th 2020Patients with Multiple sclerosis (MS) treated with mitoxantrone (MTX)—an antracyclin drug used to treat chronic refractory MS—may be at an increased risk of developing early and late left ventricular (LV) dysfunction, suggesting the need for these patients to be periodically evaluated for complications, a recent study found.
Read More
Researchers Develop Trial Protocol on Ketogenic and Fasting Diets for Patients With MS
January 17th 2020For patients with multiple sclerosis, ketogenic diets and fasting diets may be potentially safe and inexpensive complementary treatment options. However, additional clinical studies and data are needed to prove this theory.
Read More
Costs of MS Drugs Almost Triple in 7 Years
January 16th 2020The costs of disease-modifying drugs for patients with multiple sclerosis (MS) have almost tripled in 7 years, even with the introduction of generic options in the market, according to a study published by Neurology, the medical journal of the American Academy of Neurology.
Read More
Exposure to IFN-beta Among Pregnant Patients With MS Poses No Risk to Infant Size, Study Says
January 8th 2020The use of interferon-beta (IFN-beta) by pregnant patients with multiple sclerosis poses no risk to an infant’s birth weight, length, or head circumference, according to a recent study.
Read More
Dr Andrew Solomon Details Conditions Commonly Misdiagnosed as MS
January 4th 2020There are numerous conditions, including many rare and difficult to recognize disorders, which can be mistaken for MS, said Andrew Solomon, MD, associate professor of neurological sciences and division chief of multiple sclerosis at Larner College of Medicine, The University of Vermont, Burlington, Vermont.
Watch
Dr Thomas Frisell Discusses Cardiovascular Disease Risk for Patients With MS
December 30th 2019Thomas Frisell, PhD, coordinator of the Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, discusses whether patients with multiple sclerosis (MS) have an elevated risk for cardiovascular disease.
Watch
Dr Alberto Ascherio Discusses Modifiable Factors Associated With MS Progression
December 23rd 2019Alberto Ascherio, MD, DrPh, professor of epidemiology and nutrition at the Harvard T. H. Chan School of Public Health and professor of medicine at the Harvard Medical School, discusses the fact that, in addition to other modifiable factors linked with progression of multiple sclerosis (MS), dietary factors are also emerging as potentially related to outcomes.
Watch
Dr Melinda Magyari Explores What Registries Reveal About Pediatric MS
December 16th 2019Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, explores what data registry have shown about factors that are linked with secondary progression in pediatric multiple sclerosis (MS).
Watch
Dr Andrew Solomon Explains Prevalent Difficulties in Accurately Diagnosing MS
December 15th 2019MS is a difficult disease to diagnose as it can present in many different ways and lacks an attributable biomarker to assess, said Andrew Solomon, MD, associate professor of neurological sciences and division chief of multiple sclerosis at Larner College of Medicine, The University of Vermont, Burlington, Vermont.
Watch
Dr Alberto Ascherio Addresses Smoking and MS
December 9th 2019Alberto Ascherio, MD, DrPh, professor of epidemiology and nutrition at the Harvard T. H. Chan School of Public Health and professor of medicine at the Harvard Medical School, discusses the current state of knowledge on smoking and multiple sclerosis (MS) risk and the risk of MS progression.
Watch
Dr Melinda Magyari Addresses the Use of Disease-Modifying MS Therapies in Children
December 2nd 2019Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, addresses the current state of knowledge on using disease-modifying therapies to treat children with multiple sclerosis (MS).
Watch
This Week in Managed Care: November 29, 2019
November 29th 2019This week, the top managed care news included research that may hold the key to slowing progression of multiple sclerosis; Humana says it is saving billions of dollars through value-based care; the challenges of rural healthcare delivery.
Watch
Dr Alberto Ascherio Discusses Vitamin D and MS
November 25th 2019Alberto Ascherio, MD, DrPh, professor of epidemiology and nutrition at the Harvard T. H. Chan School of Public Health and professor of medicine at the Harvard Medical School, discusses the role of vitamin D insufficiency in the risk of multiple sclerosis (MS) and the optimal dose of vitamin D for patients with MS.
Watch
Patients With MS Report That Depression, Fatigue Have Strongest Effect on Quality of Life
November 15th 2019Multiple sclerosis (MS) is known to be associated with lower health-related quality of life, and a new study adds evidence that depression and fatigue are the major drivers of this relationship.
Read More
Dr Alberto Ascherio Addresses Environmental Risk Factors for MS
November 11th 2019Alberto Ascherio, MD, DrPh, professor of epidemiology and nutrition at the Harvard T. H. Chan School of Public Health and professor of medicine at the Harvard Medical School, explains that, in addition to known environmental factors that affect multiple sclerosis (MS) risk, novel factors, such as childhood obesity, are also emerging.
Watch
Researchers Identify Genes With Potential to Predict Progression and Severity of MS
November 7th 2019Researchers have identified complement genes that appear to play a role in vision loss associated with multiple sclerosis (MS), and this finding could help researchers monitor and predict the progression and severity of MS, according to a study published in Brain.
Read More
The Need for a Patient Decision Aid in Multiple Sclerosis
November 1st 2019As the number of disease-modifying therapies available for multiple sclerosis increases, patients and physicians can struggle to identify the right one for the right patient, highlighting the need for a patient decision aid.
Read More
FDA Approves Diroximel Fumarate to Treat Relapsing Forms of MS
October 30th 2019The FDA today approved Biogen and Alkermes’ diroximel fumarate, an oral agent, to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and secondary progressive disease. The drug, approved under the 505(b)(2) regulatory pathway on the basis of its bioequivalence to dimethyl fumarate (Tecfidera), will be sold as Vumerity.
Read More
Dr Jan Hillert Discusses Treatment Approaches in MS
October 28th 2019Jan Hillert, MD, PhD, professor and senior physician in the department of clinical neuroscience, Karolinska Institutet, Stockholm, Sweden, discusses whether the medical community has reached a consensus on using an escalation approach to treatment or starting with highly effective therapies in treating multiple sclerosis (MS).
Watch